Zynex Osake

Zynex EBITDA

Delisted·23.12.2025

EBITDA (Tulos ennen korkoja, veroja ja poistoja) yhtiöstä Zynex (ZYXI) 25.8.2026 päivämäärällä on 6,21 M USD. Edellisenä vuonna EBITDA (Tulos ennen korkoja, veroja ja poistoja) oli 11,75 M USD — muutos −47,12 % (matalampi).

EBITDA

6,21 MUSD

YoY

−47,12%

Viimeksi päivitetty:

EBITDA (Tulos ennen korkoja, veroja ja poistoja) yhtiöstä Zynex on 2026 6,21 M USD. EBITDA (Tulos ennen korkoja, veroja ja poistoja) yhtiöstä Zynex oli 2025 11,75 M USD. Se laskee −47,12% matalampi edelliseen vuoteen verrattuna.

Zynex EBITDA historia

  • 3 vuotta

  • 10 vuotta

  • 25 vuotta

  • Maksimi

EBITDA
Date
EBITDA
1.1.2017
8,94 M USD
1.1.2018
10,37 M USD
1.1.2019
11,07 M USD
1.1.2020
10,35 M USD
1.1.2021
22,47 M USD
1.1.2022
23,04 M USD
1.1.2023
11,75 M USD
1.1.2024
6,21 M USD
Zynex EBITDA historia
VUOSIEBITDAYoY
6,21 MUSD−47,12%
11,75 MUSD−49,00%
23,04 MUSD+2,55%
22,47 MUSD+117,08%
10,35 MUSD−6,48%
11,07 MUSD+6,71%
10,37 MUSD+15,94%
8,94 MUSD+1 951,38%
436 000,00USD−117,57%
−2,48 MUSD−56,45%
−5,70 MUSD
Access this data via the Eulerpool API

Zynex Osakeanalyysi

Mitä Zynex tekee? Zynex Inc is an American company that manufactures and distributes medical devices and accessories. The company was founded in 1996 and is headquartered in Englewood, Colorado. In recent years, it has become a major player in the pain therapy market. The history of Zynex began with the development of a neurotherapeutic system called NeuroMove, which aimed to restore mobility in patients with paralysis after strokes or other neurological disorders. The company uses proprietary technology to provide safe and effective electrotherapeutic stimulation, which helps trigger muscle contractions and improve mobility. Over the years, the company has specialized in the development and sale of medical devices for pain therapy and rehabilitation. Zynex's products can be used in various areas, including electrostimulation, TENS and EMS therapy, home diagnostics, as well as blood pressure and oxygen measurement. Zynex offers devices specifically for pain therapy. These devices are used by many doctors and physiotherapists to support patients in their healing process. The company's flagship product is the Nexus D-11 EMS and TENS device, which is capable of conducting multiple pain treatments simultaneously. Another important device from Zynex is the InWave system, which applies FDA-approved electromagnetic wave therapy. The therapy is used for both acute and chronic pain and aims to promote the body's natural healing processes to relieve pain. Zynex also manufactures home diagnostic devices such as the blood sugar monitor and pulse oximeter, which can be regularly used by patients at home to monitor their well-being. These products help individuals develop an understanding of how their body responds to different treatments or environmental conditions. An important aspect of Zynex's business model is collaborating with healthcare customers. The company forms partnerships with medical facilities and practitioners to ensure that its products are effectively and safely utilized. These partnerships often include training programs to ensure that users of each device develop a basic understanding of how it works to ensure quality treatment. Zynex has also established a subsidiary called Zynex Medical Europe, which operates in European regions. The company is based in the Netherlands and is responsible for marketing and distributing Zynex's products in Europe. Overall, Zynex has established itself as a key player in the field of pain therapy and rehabilitation. Through its innovative technology and healthcare partnerships, the company is able to provide the best possible patient care. Zynex on yksi Eurpooliin suosituimmista yhtiöistä.

Usein kysytyt kysymykset Zynex osakkeesta

Yhtiön Zynex EBITDA (Tulos ennen korkoja, veroja ja poistoja) on 6,21 M USD vuonna 2026.

EBITDA (Tulos ennen korkoja, veroja ja poistoja) yhtiöstä Zynex muuttui arvosta 11,75 M USD arvoon 6,21 M USD, mikä edustaa −47,12 % muutosta. Arvo on matalampi kuin edellisenä vuonna.

Eurpoolissa voit löytää EBITDA (Tulos ennen korkoja, veroja ja poistoja) Zynex:n täydellisen historiallisen kehityksen vuodesta 2006 lähtien – vuotuisten arvojen, kaavioiden ja yksityiskohtaisen analyysin kanssa.

EBITDA mittaa operatiivista suorituskykyä ennen rahoitusrakenteen, veroympäristön ja muiden kuin käteispoisto-osuuksien vaikutusta.

EBITDA = EBIT + Poistot

EBITDA (Tulos ennen korkoja, veroja ja poistoja):n USD on sijoittajille tärkeä tekijä. Muutokset tässä tunnusluvussa voivat signaloida parantuvia tai heikentyneitä perustekijöitä, mikä vaikuttaa suoraan osakekurssiin. Eulerpoolissa voit seurata EBITDA (Tulos ennen korkoja, veroja ja poistoja):n Zynex historiallisesti ja reaaliajassa.

Access this data via the Eulerpool API

Tuloslaskelma — Zynex

Kaikki tunnusluvut — Zynex